Prasugrel

Names

[ Name ]:
Prasugrel

[Synonym ]:
5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate
Prasugrel
Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-
Unii-34K66tbt99
Effient
Efient

Biological Activity

[Description]:

Prasugrel is a platelet inhibitor with IC50 value of 1.8 μM.IC50 value:Target: P2Y12 receptorPrasugrel is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI. Prasugrel reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 μm. From Wikipedia

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> P2Y Receptor

Research Areas >> Cardiovascular Disease

[References]

[1]. Pharmacokinetic basis of the antiplatelet action of prasugrel By Schroer, Karsten; Siller-Matula, Jolanta M.; Huber, Kurt From Fundamental & Clinical Pharmacology (2012), 26(1), 39-46.

[2]. Selective Blockade of P2Y12 Receptors by Prasugrel Inhibits Myocardial Infarction Induced by Thrombotic Coronary Artery Occlusion in Rats By Sugidachi, Atsuhiro; Yamaguchi, Shinji; Jakubowski, Joseph A.; Ohno, Kosaku; Tomizawa, Atsuyuki; Hashimoto, Masami; Niitsu, Yoichi From Journal of Cardiovascular Pharmacology (2011), 58(3), 329-334.

[3]. Darius H.Prasugrel.Hamostaseologie. 2012 Aug 1;32(3):186-90.

[4]. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.J Am Coll Cardiol. 2012 Jul 17;60(3):193-9.

[5]. Spiel AO, Derhaschnig U, Schwameis M, Bartko J, Siller-Matula JM, Jilma B.Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.Clin Sci (Lond). 2012 Nov 1;123(10):591-600.

[Related Small Molecules]

Suramin sodium | MRS 2578 | Diquafosol Tetrasodium | BPTU | AZD 1283 | Prasugrel hydrochloride | TAK-024

Chemical & Physical Properties

[ Density]:
1.347

[ Boiling Point ]:
493.5ºC at 760 mmHg

[ Melting Point ]:
122 °C

[ Molecular Formula ]:
C₂₀H₂₀FNO₃S

[ Molecular Weight ]:
373.44100

[ Flash Point ]:
252.3ºC

[ Exact Mass ]:
373.11500

[ PSA ]:
74.85000

[ LogP ]:
3.82890

[ Vapour Pressure ]:
0mmHg at 25°C

[ Index of Refraction ]:
1.619

[ Storage condition ]:
2-8°C

MSDS

Click to get detail MSDS

Safety Information

[ Hazard Codes ]:
Xi

[ RIDADR ]:
NONH for all modes of transport

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Articles

Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase.

PLoS ONE 9(10) , e110054, (2014)

Homocysteinylation of lysine residues by homocysteine thiolactone (HCTL), a reactive homocysteine metabolite, results in protein aggregation and malfunction, and is a well-known risk factor for cardio...

Effect of grapefruit juice on the bioactivation of prasugrel.

Br. J. Clin. Pharmacol. 80 , 139-45, (2015)

The P2Y12 inhibitor prasugrel is a prodrug, which is activated after its initial hydrolysis partly by cytochrome P450 (CYP) 3A4. Grapefruit juice, a strong inactivator of intestinal CYP3A4, greatly re...

Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials.

Int. J. Cardiol. 181 , 331-9, (2015)

Duration of dual antiplatelet therapy (DAPT) following drug-eluting stents (DES) remains controversial and is a topic of ongoing research.Direct and adjusted indirect comparisons of all the recent ran...